Francis C W, Marder V J, Evarts C M, Yaukoolbodi S
JAMA. 1983 Jan 21;249(3):374-8. doi: 10.1001/jama.249.3.374.
In a randomized, prospective trial of 100 patients, we have studied the safety and efficacy of warfarin sodium in comparison with that of dextran 40 in the prevention of venous thrombosis in patients at high risk for deep vein thrombosis after elective total hip or knee replacement. Warfarin was given in a new two-step regimen designed to avoid bleeding complications while still preventing venous thrombosis. A low dose of warfarin was started ten to 14 days preoperatively, and the prothrombin time was regulated to between 1.5 and 3 seconds longer than control at the time of surgery; immediately after surgery, the dose was increased to prolong the prothrombin time to 1.5 times control. The overall incidence of venous thrombosis as documented by venography was less in the 53 patients treated with warfarin than in the 37 treated with dextran (21% v 51%), as was the incidence of thrombi in the femoral or popliteal veins (2% v 16%). Objective measures of blood loss showed no difference between patients treated with warfarin or dextran, and excessive postoperative bleeding was infrequent and similar in both treatment groups. This study demonstrates that two-step warfarin therapy provides highly effective prophylaxis of postoperative venous thrombosis after elective hip or knee prosthetic surgery without excessive risk of perioperative bleeding.
在一项针对100例患者的随机前瞻性试验中,我们研究了华法林钠与右旋糖酐40相比,在择期全髋关节或膝关节置换术后深静脉血栓形成高危患者中预防静脉血栓形成的安全性和有效性。华法林采用一种新的两步给药方案,旨在避免出血并发症同时仍能预防静脉血栓形成。术前10至14天开始给予低剂量华法林,手术时将凝血酶原时间调整至比对照延长1.5至3秒;术后立即增加剂量,使凝血酶原时间延长至对照的1.5倍。静脉造影显示,接受华法林治疗的53例患者的静脉血栓形成总体发生率低于接受右旋糖酐治疗的37例患者(21%对51%),股静脉或腘静脉血栓形成的发生率也是如此(2%对16%)。失血的客观指标显示,接受华法林或右旋糖酐治疗的患者之间没有差异,术后大出血很少见,且两个治疗组相似。这项研究表明,两步华法林治疗为择期髋关节或膝关节置换术后的静脉血栓形成提供了高效的预防作用,且围手术期出血风险不会增加。